Pre-made Ravagalimab benchmark antibody ( Whole mAb, anti-CD40 therapeutic antibody, Anti-p50/Bp50/CDW40/TNFRSF5 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ravagalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ravagalimab (formerly ABBV 323), a CD40 antagonist biologic, is being developed by AbbVie, for the treatment of ulcerative colitis and Sjogren’s syndrome.
| Products Name (INN Index) | Pre-Made Ravagalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody |
|---|---|
| INN Name | Ravagalimab |
| Target | CD40 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 6pe7:HL/6pe8:HL:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | AbbVie |
| Conditions Approved | NA |
| Conditions Active | Ulcerative colitis,Sjogren's syndrome |
| Conditions Discontinued | Crohn's disease |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD40 |
| Package |
